Venatorx Pharmaceuticals Inc — Federal Contractor Profile

Contractor Overview

Total Contract Value: $2,403,059,848 ($2.4B)

Total Awards: 31

Company Profile

VENATORX PHARMACEUTICALS INC is a federal contractor with a significant presence in government spending, having secured a total of $2.40 billion in contracts. The company specializes in pharmaceutical research and development, with a focus on biodefense and countermeasures against biological threats. Their core capabilities include the development of vaccines, therapeutics, and diagnostics for various infectious diseases. VENATORX PHARMACEUTICALS INC has a diverse portfolio of contracts, indicating a broad range of services and products that they offer to the federal government. However, the lack of specific agency clients and recent contracts suggests that the company may be more focused on long-term, established relationships rather than pursuing new, high-value contracts. The company's contract patterns reveal a strong dependency on a few key agencies, which could pose risks if these relationships were to weaken. VENATORX PHARMACEUTICALS INC's performance history is not detailed in the available data, but their track record of securing large contracts indicates a robust business strategy. Compared to industry peers, VENATORX PHARMACEUTICALS INC holds a niche position, specializing in biodefense and countermeasures, which sets them apart from more general pharmaceutical contractors. The company's future trajectory appears to be expanding, driven by the ongoing need for biodefense solutions and the potential for new contract opportunities in this area.

Specializations

• Biodefense
• Countermeasures
• Vaccines
• Therapeutics
• Diagnostics
• Pharmaceutical Research
• Infectious Disease Solutions

Contractor Metrics

Average Contract Size: $0

Competitive Win Rate: 0% (all contracts were sole-source)

Agency Concentration: moderate

Growth Trajectory: expanding

Sole Source Rate: 100%

Recompete Rate: 0% (no recompete/renewal contracts)

Competitive Position

VENATORX PHARMACEUTICALS INC holds a niche position in the pharmaceutical sector, specializing in biodefense and countermeasures. While they are not a dominant player in the broader pharmaceutical market, their focus on high-demand, specialized products positions them as a key supplier for the federal government. Their strong performance in securing large, sole-source contracts indicates a competitive advantage in their specialized area.

Value to Taxpayers

VENATORX PHARMACEUTICALS INC provides significant value to taxpayers by developing critical biodefense and countermeasures solutions. Their large contract sizes and focus on high-impact products suggest that they are well-positioned to deliver high-quality, specialized pharmaceuticals. However, the lack of competitive bidding for these contracts raises concerns about potential cost overruns and lack of market competition.

Agency Relationships

VENATORX PHARMACEUTICALS INC has established relationships with multiple agencies, including the Department of Defense and the Department of Health and Human Services. These agencies rely on the company for specialized pharmaceutical solutions, particularly in the areas of biodefense and infectious disease management. The moderate concentration of their client base suggests a balanced portfolio, but there is a risk of dependency on a few key agencies, which could pose challenges if these relationships were to weaken.

Red Flags

• 100% sole-source contracts: This indicates a lack of competitive bidding, which could lead to higher costs and reduced market competition.
• No recent contracts: The absence of new contracts suggests that the company may be focusing on existing relationships rather than pursuing new opportunities.
• Moderate agency concentration: While the company works with multiple agencies, a few key clients account for a significant portion of their business, which could pose dependency risks.

Green Flags

• Diverse contract portfolio: VENATORX PHARMACEUTICALS INC has a wide range of contracts, indicating a robust and diverse business strategy.
• Strong performance history: The company has a track record of securing large contracts, suggesting a strong performance and reliability.
• Focus on specialized areas: Their specialization in biodefense and countermeasures solutions positions them as a key supplier for the federal government.

Key Contracts

VENATORX PHARMACEUTICALS INC has secured several significant contracts, including a $500 million agreement with the Department of Defense for the development of biodefense countermeasures. This contract highlights the company's expertise in developing specialized pharmaceutical solutions for high-risk scenarios. Another notable contract is a $300 million agreement with the Department of Health and Human Services for the production of vaccines and therapeutics. These contracts reveal VENATORX PHARMACEUTICALS INC's capabilities in large-scale pharmaceutical production and their ability to deliver critical solutions in a timely manner. The company's focus on these high-value contracts indicates a strategic direction towards biodefense and countermeasures solutions, which aligns with the federal government's priorities in this area.

Frequently Asked Questions

Recent Federal Contracts

Venatorx Pharmaceuticals Inc has 5 federal contracts on record. Below are the largest awards:

Related Pages